Helicobacter Pylori Infection Pipeline Insight Report 2024: Insights About 5+ Companies and 5+ Pipeline Drugs Featuring TenNor Therapeutics, Servatus Biopharmaceuticals, and TenNor Therapeutics lelezard.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lelezard.com Daily Mail and Mail on Sunday newspapers.
Sichuan Kelun-Biotech will partner seven preclinical antibody-drug conjugate assets with Merck in a deal that pays Kelun-Biotech $175 million upfront and up to $9.3 billion in milestones.
TenNor Enters Research Collaboration with Janssen for Potential New Treatments for Nontuberculous Mycobacteria Diseases
News provided by
Share this article
Share this article
SUZHOU, China, Jan. 18, 2021 /PRNewswire/ TenNor Therapeutics (Suzhou) Limited, a clinical-stage biopharmaceutical company dedicated to research and development of differentiated products for the treatment of diseases associated with bacterial infections and dysbioses, announced today that it has entered into a research collaboration agreement with Janssen Pharmaceuticals, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson. As part of the agreement, the parties plan to utilize a multitargeting drug conjugation platform developed by TenNor to discover new therapies for the treatment of nontuberculous mycobacteria (NTM) diseases. The agreement was facilitated by Johnson & Johnson Innovation LLC.